Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebound Pain After Volar Plate Surgery in Infraclavicular Brachial Plexus Block With Ropivacaine 3.75 mg/ml Compared With 7.5 mg/ml
NCT06950372Phase 4Completed
- Sponsor
- Oslo University Hospital
- Start
- Feb 2025
- Primary completion
- Apr 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial of ropivacaine (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Worst pain score during the first 48 hours after surgery. Started Feb 2025; status: completed.
02
Drugs
ropivacaine
Beyond the preview
Go deeper on NCT06950372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06950372.